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354 The Journal of Thoracic and Cardbjective: During ex vivo perfusion with human blood, homozygous galactosyl
ransferase knockout swine lungs exhibit prolonged survival (2 hours) relative to
ild-type (15 minutes) and swine lungs expressing human decay accelerating
actor (1 hour). In this study, the in vivo behavior of galactosyl transferase
nockout lungs was evaluated.
ethods: Three galactosyl transferase knockout swine left lungs were transplanted into
aboons in a life-supporting model. One baboon lung allograft and two swine lung
enografts transgenic for human membrane cofactor protein (CD46) served as controls.
esults: Whereas two membrane cofactor protein lungs exhibited high pulmonary
ascular resistance (500 mm Hg · min/L) and failed to support life within 21
inutes, two of three galactosyl transferase knockout lungs supported life, for 90
nd 215 minutes, and displayed low peripheral vascular resistance (48 12 mm Hg
min/L at 60 minutes), similar to the allogeneic control. Complement activation
delta C3a  250 ng/mL through 60 minutes) and C5b-9 deposition were minimal
n both galactosyl transferase knockout and membrane cofactor protein lungs.
eutrophils, monocytes, and platelets were rapidly sequestered in galactosyl trans-
erase knockout and human membrane cofactor protein lung recipients, unlike the
llogeneic control (20%); and thrombin formation (delta plasma fraction 12 
.5 nmol/L) was seen in the galactosyl transferase knockout recipients. Platelet
ctivation (-thromboglobulin rise  200) and appearance of capillary congestion
nd vessel thrombosis confirmed coagulation activation associated with galactosyl
ransferase knockout lung failure.
onclusions: Galactosyl transferase knockout swine lungs are significantly protected in
ivo from the physiologic consequences (increased pulmonary vascular resistance,
apillary leak) associated with hyperacute lung rejection. As during ex vivo perfusion,
ysregulated coagulation—thrombin elaboration, platelet activation, and intravascular
hrombosis—mediates galactosyl transferase knockout lung xenograft injury.
dvances in surgical technology, critical care, and immunosuppression have
markedly improved both short- and long-term survival of solid-organ
transplants. However, the shortage of human organ donors remains a majorimitation in the field of transplantation. Considerable progress has been made in the
iovascular Surgery ● May 2007
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TXeld of xenotransplantation over the past several decades,1-6
lthough hyperacute rejection has remained particularly
roblematic. To this end, a variety of transgenic swine have
een engineered in the hope of abrogating hyperacute re-
ection by inhibiting complement activation. Although this
pproach has been met with some success in human com-
lement regulatory protein transgenic kidneys and hearts,6-8
rotection of human decay accelerating factor-positive
hDAF) () lungs was disappointing.4,8-12 In our prior ex-
erience with three hDAF transgenic swine lungs transplanted
nto cynomolgus monkeys,13 life-supporting xenogenic lung
unction was rarely observed for more than a few minutes.
he combination of an hDAF () lung, C1 esterase inhib-
tor (Behrinert-P; Behringer, Mannheim, Germany), throm-
oxane and histamine inhibition, methylprednisolone, and
nhaled nitric oxide was also tried in three baboon lung
enograft recipients without dramatic success. In one case,
dditional use of Gal-column immunoadsorption daily for
days before transplant yielded 7 hours of life-supporting
urvival in a baboon lung transplant recipient without any
notrope requirement.14 The lung in this recipient ultimately
ad marked perivascular edema and lymphatic dilation in
he lobular septa, with intravascular thrombi, and histologic
haracteristics in small arterioles evidencing endothelial
ctivation. This approach was not successful when applied
n two additional animals that had previously been sensi-
ized during rejection of a previous swine heart graft.
Because the carbohydrate structure Gal1-3Gal is the
ntigen recognized by over 80% of anti-swine antibody
aturally found in human beings, genetically modified
alactosyl transferase knockout (GalT-KO) swine have
een developed that do not express this moiety.15,16 Al-
hough heart and kidney transplants from GalT-KO swine
ppear to be reliably protected from hyperacute rejec-
ion,17,18 our own results in ex vivo lung perfusion studies
ave been disappointing.19 Although physiologic transpul-
onary blood flow, low peripheral vascular resistance
PVR), and markedly prolonged survival compared with
ild-type and hDAF lungs were observed, lung failure
evertheless occurred after an average of 2 hours resulting
rom loss of pulmonary vascular barrier function (pulmo-
Abbreviations and Acronyms
TG  beta-thromboglobulin
ELISA  enzyme-linked immunosorbent assay
F12  fragments 12
GalT-KO galactosyl transferase knockout
hDAF  human decay accelerating factor
hMCP  human membrane cofactor protein
MCP membrane cofactor protein
PVR  peripheral vascular resistanceary edema) and/or intravascular thrombosis. c
The Journal of ThoracicAlthough our ex vivo lung perfusion model is widely
stablished and simulates most physiologic in vivo condi-
ions, exposure of blood to artificial surfaces and concom-
tant intensive anticoagulation introduce potentially con-
ounding variables. Thus, this in vivo study, the first to
escribe GalT-KO swine lung function in nonhuman pri-
ates, was designed to determine whether the observations
x vivo predict in vivo performance, and specifically to
etermine whether a GalT-KO lung xenograft is able to
upport the life of a nonhuman primate.
aterials and Methods
nimals
enetically engineered swine expressing human membrane cofac-
or protein (hMCP; n  2, 60 kg) were provided by the Mayo
linic (Rochester, Minn). GalT-KO swine (20–60 kg) were sup-
lied by Immerge, Inc (n  2; Boston, Mass) and Revivicor Inc (n
1; Blacksburg, Va). Six Papio anubis baboons (21–25 kg;
uckshire Corporation, San Antonio, Tex) served as lung recipi-
nts; and a baboon that had remotely rejected swine heart xeno-
raft was a lung allograft donor. All procedures were approved by
he University of Maryland Animal Care and Use Committee and
ere in compliance with guidelines from NIH publication 86-23,
he “Guide for the Care and Use of Laboratory Animals.”
ung Transplant Model
alT-KO lungs were harvested remotely either in Boston or Pitts-
urgh and transported with a cold ischemic time of approximately
hours. Two hMCP swine lung donors and one baboon lung donor
ere sedated with 20 mg/kg ketamine and 1 mg/kg xylazine
Phoenix Pharmaceutical Inc, St Joseph, Mo) and given diphen-
ydramine (Benadryl; Pfizer, Morris Plains, NJ) 10 to 25 mg and
anitidine 2 mg/kg. Anesthesia was induced and maintained with
soflurane 1% to 3%. After median sternotomy and vascular iso-
ation, heparin was administered (500 IU/kg), and an aortic can-
ula was secured in the pulmonary artery. Next, 1-benzylimidazole
5 mg/kg, a thromboxane synthase inhibitor; Sigma No. 116416, St
ouis, Mo) and prostacyclin analog (Flolan 0.03 mg/kg; Glaxo-
mithKline, Research Triangle Park, NC) were injected by slow
olus infusion into the right heart. Cardiac inflows were occluded,
nd the lungs were flushed with cold (4°C) Perfadex (Vitrolife,
ungsbacka, Sweden) containing Flolan 0.5 mg/L and nitroglyc-
rin 10 mg/L. Cold saline slush was applied to the lungs. After
xcision of the heart–lung block, the left lung was prepared for
ransplant into the baboon, and the right lung was prepared for ex
ivo perfusion with heparinized fresh human blood as previously
escribed.19
Baboon recipients were sedated with 10 mg/kg ketamine, in-
ubated, and maintained under general anesthesia with isofluorane
% to 3%. A femoral arterial line, a femoral vein sheath, and
dditional intravenous access were secured. Heparin was bolused
t 70 IU/kg and then infused at 200 U/h to maintain activated
lotting time greater than 200. The recipients were treated with
iphenhydramine (0.50–1 mg/kg), ranitidine (2 mg/kg), and 1-
enzylimidazole (7 mg/kg). Nitric oxide (INO Therapeutics, Clin-
on, NJ) was delivered to the inspiratory limb of the ventilator
ircuit and calibrated to deliver 40 ppm. One recipient of an hMCP
and Cardiovascular Surgery ● Volume 133, Number 5 1355
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1
TXung was additionally treated with bivalirudin (Hirulog; The Med-
cines Company, Cambridge, Mass) 1 mg/kg bolus before graft
evascularization and continuous infusion of 2.5 mg · kg1 · h1.
clamshell incision was made at the fourth intercostal space. A
ow-directed catheter introduced from the femoral vein was posi-
ioned in the pulmonary artery with assistance of direct cardiac
anipulation. The right pulmonary artery was isolated with a
nared vessel loop, the left hilar structures dissected and occluded,
nd the left lung removed. The bronchial anastomosis was per-
ormed first, followed by arterial and venous anastomoses. Just
efore revascularization, methylprednisolone (SoluMedrol, 10 mg/
g; Pfizer-Pharmacia, Morris Plains, NJ), C1 esterase inhibitor
Behrinert, 50IU/kg; Behringer), and 1- benzylimidazole (2.5 mg/
g; Sigma) were given to the recipients by slow bolus infusion.
efore and after graft reperfusion, blood and tissue biopsy speci-
ens were collected serially at predetermined time points for in
itro analysis. Vascular flow probes (Transonic Systems Inc,
thaca, NY) on the aorta and left pulmonary artery continuously
easured cardiac output and flow to the transplanted lung, respec-
ively. Thirty minutes after graft reperfusion, flow to the right
native) lung was progressively occluded by snaring the right
ulmonary artery to assess the capacity of the transplanted lung to
upport life. If the animal was unstable with right pulmonary artery
cclusion, the right pulmonary artery snare was released, and hemo-
ynamic support was initiated with titrated norepinephrine, vasopres-
in, and dopamine. The right pulmonary artery was resnared at 15- to
0-minute intervals for 90 to 120 minutes, and hemodynamics was
ecorded; if improvement in lung function was not observed on serial
ssessment, the experiment was terminated. Graft survival was de-
ned as duration of life-supporting lung function.
istology and Immunochemistry
erial lung biopsy specimens after reperfusion and multiple ter-
inal samples were obtained, trisected, and processed as follows.
ormalin-fixed, paraffin-embedded sections were stained with he-
atoxylin and eosin for light microscopy and analyzed qualita-
ively for intravascular thrombosis and interstitial, alveolar, or
arger airway edema and hemorrhage. Two other pieces were
nap-frozen in liquid nitrogen, one without further manipulation
nd the other after gentle syringe instillation into a visible bron-
hiole of OCT diluted with saline using a small-gauge angiocath-
ter. Frozen tissue sections from OCT-infused biopsy specimens
ere assessed by immunohistochemistry as previously described4
ith monoclonal antibodies against human C5b-9 (Dako, Copen-
agen, Denmark) at 1:50, C4d at 1:50 (Quidel Corporation, San
iego, Calif), CD41 (Immunotech, Marseilles, France) at 1:100,
y3-labeled goat-anti-mouse immunoglobulin G (Jackson Labo-
atories, West Grove, Pa), rabbit anti-von Willebrand factor anti-
ody (Dako), and Cy2-labeled goat-anti-rabbit immunoglobulin G
ntibody (Jackson Laboratories). The deposition of platelets in
ung tissue was judged by the staining intensity (from to),
aking into account the extent and intensity of staining from a
tandard control section.
eta-thromboglobulin, Thrombin, and Complement
nzyme-linked Immunosorbent Assays
eta-thromboglobulin (TG) and prothrombin fragments 12F12) were measured by commercial enzyme-linked immu- p
356 The Journal of Thoracic and Cardiovascular Surgery ● Maosorbent assay (ELISA; Asserachrome-TG; Diagnostica Stago,
arsippany, NJ; and Enzygnost micro F12; Dade Behring, Mar-
urg, Germany) in plasma samples collected in CTAD tubes
Becton Dickinson, Franklin Lakes, NJ; BD No. 367947) contain-
ng 0.109 mol/L buffered sodium citrate, 15 mmol/L theophylline,
.7 mmol/L adenosine, and 0.198 mmol/L dipyridamole. C3a was
easured by ELISA (C3a ELISA; Quidel, San Diego, Calif) in
lasma samples stored in ethylenediaminetetraacetic acid at
70°C.
low Cytometry Staining of Platelet Activation
lood samples collected in CTAD tubes were immediately
xed with HEPES-buffered saline plus 1% paraformaldehyde to
revent in vitro activation. Platelet activation was detected by
etecting the expression of CD62P by flow cytometry as pre-
iously described.5 Owing to technical difficulties with sample
rocessing and platelet staining protocols, these data are avail-
ble for only the last two GalT-KO lung xenograft experiments
nd for the allograft study.
ematologic Analysis
hite blood cells, neutrophils, monocytes, and platelets were
numerated by both standard automated (Cell-Dyn; Abbott, Abbott
ark, Ill) and manual differential techniques in blood samples
ollected in ethylenediaminetetraacetic acid.
esults
ung Survival and Function
he baboon recipient of an allogenic lung exhibited nor-
al physiologic flow to the transplanted lung on revas-
ularization (0.8 L/min) and was able to support life with
he right pulmonary artery occluded for more than 24
ours, until elective termination of the experiment. As
hown in Figure 1, A, and summarized in Table 1, PVR
as stable throughout the experiment around 30 mm
g/L/min. Arterial oxygen tension measured from arte-
ial blood ranged from 400 to 600 mm Hg on 100%
xygen.
The recipient of hMCP transgenic swine lung without
hrombin inhibition had minimal transpulmonary flow
10% of cardiac output) for the duration of the experi-
ent; PVR was greater than 200 mm Hg/L/min. At 30
inutes after revascularization, when the recipient’s native
ung was clamped, blood flow to the transplanted lung
emained minimal, and PVR exceeded 400 mm Hg/L/min,
hich was associated with immediate hemodynamic col-
apse. Arterial oxygen tension measured from arterial blood
anged between 60 and 90 mm Hg on 100% oxygen.
The right pulmonary artery was reclamped periodically
ver the next 90 minutes, but flow to the transplanted lung
emained low, and the animal was put to death.
The hMCP lung recipient treated with bivalirudin exhib-
ted blood flow to the transplanted left lung (0.45 L/min)
hat was 40% of cardiac output (1.1 L/min). When the right
ulmonary artery was snared, the left lung accommodated
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TXhe full cardiac output of 1.0 L/min, and the transplanted
ung supported the recipient life for a total of 21 minutes.
ltimately, hypoxemia (arterial oxygen tension 35 mm Hg)
as associated with bradycardia and hypotension and led to
igure 1. Pulmonary vascular resistance (PVR) (A) and plasma
evels of complement fragments C3a (B) of all lung recipients.
ime 30 represents the initial revascularization of the grafts.
ime 0 marks the time when right pulmonary artery to the native
ung was clamped and the life-supporting function of the grafts
as assessed. C3a levels are expressed as the amount of com-
lement fragments produced above the baseline (). The legend
n this figure applies to all following figures. The long-dash line
epresents the allogenic lung. Two short-dash lines stand for
embrane cofactor protein (MCP) lungs, and three solid lines for
alactosyl transferase knockout (GalT-KO) lungs. Open symbols
epresent nonfunctional lungs and filled symbols represent lungs
hat were able to support life.he termination of the experiment. s
The Journal of ThoracicOne GalT-KO lung (No. 1) failed to support life owing to
igh PVR. The other two GalT-KO lungs (Nos. 2 and 3)
ere life-supporting for 225 and 90 minutes, respectively.
he recipient of GalT-KO No. 2 lung exhibited tracheal
dema at 2 hours, associated with decline in arterial oxygen
ension from 390 to 84 mm Hg; arterial oxygen tension
emained low for the remainder of the experiment. PVR
emained low and cardiac output stable for approximately 4
ours, when pulmonary flow dropped from 0.5 to 0.2 L/min.
uring the last 5 minutes of the experiment, systemic blood
ressure dropped and the animal died. GalT-KO No. 3 lung
urvived 90 minutes with physiology similar to the lung
llograft (PVR remained low at 100 mm Hg/L/min), but
rogressive tracheal edema impeding ventilation and oxy-
enation led to recipient death. Of note, this recipient had
ome native lung pulmonary edema before xenograft revas-
ularization. The cause of the acute injury to the native lung
n this instance is unknown.
omplement Activation
elative to prolific complement activation seen during
erfusion of wild-type lungs ex vivo (1000 ng/mL),4 in
ivo perfusion of five genetically modified lungs in this
xperience was associated with minimal increase in C3a
Figure 1, B). Lung C4d and C5b-9 deposition was min-
mal at all time points (not shown), suggesting that in
ivo perfusion of these lungs with baboon blood did not
esult in significant complement activation systemically
r in the swine lung.
latelet Sequestration and Activation Markers
latelet counts were minimally perturbed after graft revascu-
arization and institution of life-supporting lung function by the
llograft (Figure 2, A), and there was no detectable platelet
ctivation (CD62P expression in circulating platelets, Figure 2,
; TG elaboration, Figure 2, C). In contrast, platelet counts
ell by 18% to 60% after xenograft reperfusion and/or conver-
ABLE 1. Summary of experimental outcomes
reatment
roup Cause of failure
Graft survival
Total
(min)
Life-supporting
(min)
CP Poor flow 30 0
CP 
bivalirudin
High PVR 51 21
alT-KO No. 1 Poor flow 30 0
alT-KO No. 2 Tracheal edema 255 225
alT-KO No. 3 Tracheal edema 120 90
llogenic Elective termination 24 h 24 h
CP, Membrane cofactor protein; GalT-KO, galactosyl transferase knock-
ut; PVR, peripheral vascular resistance.ion to life-supporting graft perfusion, accompanied by varying
and Cardiovascular Surgery ● Volume 133, Number 5 1357
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1
TXegrees of activation in residual circulating platelets. hMCP
xpression or additional thrombin inhibition did not prevent
latelet sequestration or activation. GalT-KO No. 1, which
ad minimal graft perfusion, exhibited little decline in
latelet number after reperfusion and partial recovery
uring the observation interval. GalT-KO lungs 2 and 3
xhibited a sharp initial fall in circulating platelet number
fter xenograft reperfusion and a further subsequent de-
line over 90 to 225 minutes of life-supporting lung
enograft function. Activation of those platelets remain-
ng in the circulation was minimal in the recipient of
alT-KO lung No. 2, and marked (78% at 90 minutes) in
he recipient of GalT-KO No. 3. In the three experiments
n which both CD62P expression and TG were assayed,
esults were concordant.
oagulation Activation Marker—F12 and Thrombin
ormation
ignificant thrombin formation (F12 increase  0.2, Figure
, D) was observed after lung allotransplantation and in every
ung xenograft except for the hMCP lung treated with the
irect thrombin inhibitor bivalirudin. That experiment aside,
igher thrombin levels were measured in association with
hysiologic xenograft perfusion. Interestingly, although the
Figure 2. Platelet and coagulation cascade activation
described in Figure 1. Platelet activation was assess
measured by automated complete blood count (A),
thromboglobulin (BTG) from  granules (C). Activation
of thrombin measured by fragments 12 (F12) (D). Allogenic lung showed a slight rise in thrombin formation after a
358 The Journal of Thoracic and Cardiovascular Surgery ● Maeperfusion, no further increase was detected throughout the
ext 24 hours (data after 4 hours are not shown).
lood Cell Counts
eutrophil counts fell with high PVR and low transpul-
onary blood flow through the MCP lung without biva-
irudin treatment, but not in the allograft that had phys-
ologic transpulmonary blood flow (Figure 3). Neutrophil
ounts declined 35% to 45% after reperfusion of
alT-KO lungs 2 and 3, which subsequently supported
ife, but not in the life-supporting bivalirudin-treated
CP lung or in GalT-KO lung 1, which did not support
ife. No consistent trend was manifest in association with
nstitution of life-supporting function or subsequent graft
ailure. Circulating monocyte counts fell 30% to 70%
uring initial reperfusion of all grafts with physiologic
lood flow (bivalirudin-treated MCP, GalT-KO Nos. 2
nd 3, as well as the allograft) and tended to fall in
ssociation with xenograft failure except in the instance
n which thrombin was inhibited.
istology and Immunohistochemistry
istologic examination of lung biopsy specimens by hematox-
lin and eosin staining is shown in Figure 4. The allogenic lung
e of all lung recipients. Symbols correlate with those
y quantifying platelet sequestration from circulation
ession of CD62P marker (B), and release of beta-
e coagulation cascade was detected by the formation
ta are expressed as change from the baseline ().profil
ed b
expr
of th
ll dat 24 hours retained normal microscopic anatomy with clear
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TXlveoli, thin septae, and no intravascular thrombosis (Figure 4,
). There was severe intra-alveolar, interstitial, and intratra-
heal hemorrhage in hMCP lung treated with bivalirudin, a
eature unique to this recipient. At failure, GalT-KO lungs
xhibited prevalent intravascular thrombosis (Figure 4, C) and
rominent septal vascular congestion (Figure 4, D). Immuno-
istochemical staining of lung biopsy specimens for platelet
eposition (CD41) is shown in Figure 5. Allogenic lung at 24
ours showed no platelet deposition, as expected (Figure 5, A
nd B). Likewise, GalT-KO lung at 30 minutes showed min-
mal platelet deposition (Figure 5, C and D). In contrast,
alT-KO lung at failure showed intense platelet deposition
ssociated with von Willebrand factor positive endothelial
tructures (Figure 5, E and F).
iscussion
his in vivo lung xenograft experience using three
igure 3. Neutrophil (A) and monocyte (B) sequestration from
irculation. Symbols correlate with those described in Figure 1.
ell numbers are expressed as percent remaining in circulation
sing the cell counts before graft revascularization as the
aseline.alT-KO and two hMCP grafts confirms and extends our e
The Journal of Thoracicechanistic understanding of acute lung xenograft injury
ased on an ex vivo perfusion model with human blood.
wo of three GalT-KO lungs supported the recipient in a
tringent, life-supporting single-lung transplant model. Fail-
re of these grafts was associated with direct (thrombin
ormation, intravascular platelet deposition) and indirect
platelet activation) evidence of intravascular thrombosis,
ust as in our previous report.19 Similarly, we find that direct
hrombin inhibition significantly improves transpulmonary
lood flow and permits transient life-supporting function of
baboon by a swine lung expressing a human complement
egulatory protein, hMCP. However, by itself, hMCP ex-
ression was not sufficient to support life in one experiment.
As part of our ongoing studies using a different model,
he right lungs of the GalT-KO No. 2 and No. 3 experiments
ere perfused ex vivo with human blood (manuscript in
reparation). Interestingly, in these ex vivo experiments,
oth the tempo of graft failure (6 hours in GalT-KO No.
and 56 minutes for GalT-KO No. 3) and mode of graft
ailure (sudden loss of transpulmonary graft flow versus loss
f pulmonary capillary barrier function, respectively) were
imilar for each pair of lungs studied contemporaneously in
oth in vivo and ex vivo experiments. The histologic fea-
ures of ex vivo perfused lungs also showed intravascular
hrombosis at the time of graft failure. These preliminary
bservations suggest that our ex vivo model is useful for
redicting in vivo lung xenograft behavior, while illustrat-
ng the importance of confirming hypotheses developed
ith ex vivo perfusion in a life-supporting model.
In outbred swine, Yeatman,9,10 Kulick,11 Gonzalez-Staw-
nski,20 and their colleagues have previously obtained pro-
onged lung function by inhibiting complement, adsorbing
nti-swine antibody, and supporting animals with high-dose
ressors. However, these models only rendered the recipient
ntermittently dependent on function of the graft.9-11,20
lthough constructs such as this can provide useful mech-
nistic information, in vivo models that do not mandate
ontinuous life support and ex vivo perfusion systems using
onphysiologic perfusion criteria (low flow, high pressure,
r perfusates lacking critical formed blood elements such as
latelets or nucleated cells) may not accurately predict
unctional capacity of the graft in vivo.21
On the basis of C3a elaboration and immunohistologic
nalysis, both hMCP and GalT-KO lung xenografts are well
rotected with respect to antibody-driven classic pathway
omplement activation. Although these genetic modifica-
ions are effective in blocking their targeted pathway, hy-
eracute rejection still occurs, presumably driven primarily
y other, complement-independent pathways.22-24 Our cur-
ent and prior observations suggest that efficient regulation
f complement alone is inadequate to permit clinically
seful function of porcine lung in a human blood
nvironment.4,22-24
and Cardiovascular Surgery ● Volume 133, Number 5 1359
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1
TXPlatelet and coagulation activation occur consistently in
he context of discordant organ xenotransplantation.25-28
hereas the lung allograft recipient had minimal platelet
equestration and only a modest degree of thrombin forma-
ion, in all three recipients of physiologically reperfused
ung xenografts 30% to 60% of platelets were sequestered
rom the circulation within 30 minutes after revasculariza-
ion, and thrombin formation was also high in all three
alT-KO lung recipients. Intravascular thrombosis and tis-
ue platelet deposition at the time of lung failure further
trongly support our working hypothesis that coagulation
ctivation is the cause of ultimate graft demise. However,
ince we have not examined potential differences in levels
f donor-reactive anti-swine antibodies among the primate
ecipients, it remains possible that anti-swine antibodies
anti-Gal for MCP lungs and anti–non Gal for GalT-KO
ungs) might serve as the primary initiator of the events that
ltimately lead to lung injury. Nonetheless, it appears that,
o achieve long survival of GalT-KO lungs, the etiology of
oagulation dysregulation needs to be addressed indepen-
ently from complement activation.
Coagulation cascade activation can be prevented ei-
her directly or indirectly at the level of thrombin forma-
ion and/or platelet activation. In this study, bivalirudin,
direct thrombin inhibitor, controlled thrombin production,
imiting the rise in PVR, and prolonged life-supporting
ime. This replicates our previous experience ex vivo
here bivalirudin significantly improved mean lung sur-
ival, from 8 to 77 minutes, even in the context of intact o
360 The Journal of Thoracic and Cardiovascular Surgery ● Mantibody and complement-driven mechanisms.29 Impor-
antly, bivalirudin also consistently delayed complement
ctivation, similar to combined platelet receptor block-
de.22 We infer that endothelial thrombin formation,
hich occurs in the context of xenotransplantation even
ith quiescent endothelial cells,27 may be a crucial pri-
ary stimulus for the initiation of platelet aggregation
nd activation, and thus for complement cascade ampli-
cation during hyperacute lung rejection, and may be
xpected to occur even if antibody and complement are
emoved from the equation. Although thrombin is one
mportant platelet activator, there are many other ago-
ists/platelet receptor pairs that likely will need to be
onsidered, including von Willebrand factor and glyco-
rotein Ib.
Although bivalirudin effectively blocked thrombin for-
ation and intravascular thrombosis in the hMCP graft,
ung failure was associated with interstitial and alveolar
emorrhage, indicative of profound loss of endothelial bar-
ier function. If caused by antibody-mediated injury, as
eems probable, GalT-KO lungs should be less susceptible
o this phenomenon.
Peterson and associates30 demonstrated that human mono-
ytes adhere to swine endothelial cells by binding to the -Gal
ntigen, which not only causes monocyte sequestration in the
issue but also acts as a trigger to upregulation of endothelial
ells’ adhesion molecule, cytokine, and tissue factor expres-
ion. It is interesting that, in this study, we found sequestration
Figure 4. Hematoxylin and eosin histo-
logic studies of lung biopsy speci-
mens. Allogenic lung (A) at 24 hours
showed normal lung histologic fea-
tures with thin alveolar septae and no
pulmonary edema or intravascular
thrombosis. Membrane cofactor pro-
tein lung  bivalirudin (B) showed se-
vere interstitial/alveolar hemorrhage
extending to the airway but no intra-
vascular thrombosis. GalT-KO lung
showed significant intravascular
thrombosis (C) and severe septal vas-
cular congestion (D) at failure.f monocytes from circulation in all four functional lungs,
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TX
ncluding the allogeneic lung and the two GalT-KO lungs.
owever, more data are needed to confirm these observations
nd discern their physiologic significance.
In summary, we have shown that whereas human com-
lement regulatory protein transgenic lungs failed to sup-
ort life without additional treatment to the recipient,
alT-KO lungs were able to do so for as long as 3.5 hours.
ur associated findings support our working paradigm that
ysregulated coagulation participates directly in GalT-KO
ung injury. Our model postulates that primate monocytes
nd porcine intravascular macrophages trigger local coagu-
ation pathway activation through release of tissue factor
hen activated by antibody, complement, or local thrombin
ormation. Tissue factor in turn initiates and amplifies plate-
et aggregation as well as activation of endothelial cells and n
The Journal of Thoracicplethora of other cell types in lung and blood. Dysfunc-
ional thromboregulatory processes in the setting of xeno-
ransplantation fail to abort amplification of several pro-
hrombotic cascades,25-28 leading to prolific intravascular
oagulation and concomitant complement activation. In our
stimation, improved mechanistic definition of the interac-
ion between these various triggers—antibody, complement,
dhesion molecules, platelets, and other coagulation path-
ay constituents—will be necessary to devise efficient,
ractical strategies for aborting the various pathogenic pos-
tive feedback loops outlined here, and thus to develop
linically suitable approaches for lung xenografting.
The work is supported by kind gifts from INO Therapeutics for
Figure 5. Immunohistochemistry stain-
ing for platelet deposition (CD41) of
lung biopsy specimens. The green and
red colors represent von Willebrand
factor (endothelial marker) and CD41
(platelet marker), respectively. Allo-
genic lung (A and B) at 24 hours
showed essentially no platelet deposi-
tion. Likewise, GalT-KO lungs at 30
minutes (C and D) exhibited minimal
platelet deposition. However, at lung
failure (E and F), there was prominent
platelet deposition (red) in association
with alveolar septal endothelium
(green) in the GalT-KO lung.itric oxide gas supply and accessories, Boehringer Ingleheim for
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iscussion
r Joseph B. Zwischenberger (Galveston, Tex). As one ap-
roaches the problem of an off-the-shelf artificial lung, the spec-
rum ranges from aplastic artificial lung all the way to transspecies
ransplant. You are to be congratulated for persisting in your work
f trying to accomplish transspecies transplantation, which has the
romise for an off-the-shelf artificial lung.
This work has been ongoing for 10 or 15 years, and it strikes
e that creating a transgenic knockout swine model is very diffi-
ult. You did not mention what it takes to create that. Could you
lease recap that for us?
Second, I am having some difficulty in trying to put together
he accomplishment of a 2-hour survival in two of three pigs. How
s two of three an advance?
Finally, you mentioned intravascular coagulation as being the
allmark of the failure of these transplanted lungs, and you men-
ioned platelet activation and intravascular thrombosis. Could you
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Nguyen et al Cardiothoracic Transplantationease out which is the chicken and which is the egg? Are you
ctivating platelets, which are then causing intravascular coagula-
ion? Are you causing intravascular coagulation, which is then
ctivating platelets? It may help to define your future strategies.
Dr Nguyen. Thank you, Dr Zwischenberger. To answer your
rst question about how to make the GalT-KO lungs, I wish I knew
ecause then I would be able to make them myself and make them
ore available. These are very precious animals because they are
enetically engineered by only a few groups and we have to share
hem among many investigators in the field. My understanding is
hat they can either be cloned or bred naturally. The problem is that
hey do not breed as well as the other domestic swine and some-
imes they have a higher rate of perinatal mortality as well.
owever, if they survive to adulthood, then they have no other
ealth problems so far as we know.
To answer your second question about whether two of three
alT-KO lungs surviving at 4 hours is an achievement, I think this
s phenomenal. If you attach wild-type lungs or even transgenic
CP lungs untreated to a baboon, you do not have any life-
upporting function beyond minutes. In the past many other in-
estigators did in vivo transplant. You have to do many treatments
o the recipient in terms of antibody absorption before surgery. A
ot of manipulation to the recipient sometimes is not beneficial to
he recipient. Thus I think two of three lungs beyond 1 hour and 4
ours is significant. u
The Journal of ThoracicYour third question concerned intravascular thrombosis and
hether the coagulation activation starts first or platelet activation
tarts first. I think it is more of a circle feedback loop. If you perfuse
uman blood to a pig organ, even in the nonactivated pig endothelial
ells, you do see human prothrombin converted to thrombin, because
ig thrombomodulin is so ineffective at preventing this process.
uman thrombomodulin is very effective in doing this, but not pig
hrombomodulin. Thus you have thrombin formation. Even in the
bsence of complement activation, you have thrombin formation first,
nd then you could trigger coagulation activation directly from throm-
in. However, then thrombin can also activate platelets, and activated
latelets can trigger coagulation activation as well. Again, I think it is
ore like a circle feedback loop. We have to address both platelet
ctivation and coagulation activation together to prevent intravascular
hrombosis.
Dr Young Tae Kim (Seoul, South Korea). Did you look at the
on Willebrand factor? We have been doing similar experiments,
nd what we found is that when we deplete the von Willebrand
actor by giving vasopressin, the success rate increases. Did you
heck it?
Dr Nguyen. Do you mean check for the absence of GalT
ntigen in GalT-KO pigs?
Dr Kim. The von Willebrand factor.
Dr Nguyen. Yes. We did not do this ourselves, but the supplier
f the GalT-KO pigs actually confirmed that. Every time they sent
s the pigs, they confirmed that this is indeed GalT-KO.
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